Armstrong, April
Blauvelt, Andrew
Simpson, Eric L.
Smith, Catherine H.
Herranz, Pedro
Kataoka, Yoko
Seo, Seong Jun
Ferrucci, Silvia M.
Chao, Jingdong
Chen, Zhen
Rossi, Ana B.
Shumel, Brad http://orcid.org/0000-0002-9285-8164
Tomondy, Paul
Clinical trials referenced in this document:
Documents that mention this clinical trial
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
https://doi.org/10.1007/s13555-022-00822-x
Documents that mention this clinical trial
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
https://doi.org/10.1007/s13555-022-00822-x
Documents that mention this clinical trial
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
https://doi.org/10.1007/s13555-021-00630-9
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
https://doi.org/10.1007/s13555-021-00643-4
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
https://doi.org/10.1016/s0140-6736(15)00388-8
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s40257-022-00685-0
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 14 September 2021
Accepted: 3 November 2021
First Online: 13 December 2021